On Dec. 16, 2020, Meridian Bioscience announced that it had been awarded funding in the amount of approximately $1M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative, to expedite the launch of the companyﾒs SARS-CoV-2 molecular diagnostic test on the Revogeneﾮ platform.

On Dec. 7, the application for Emergency Use Authorization (EUA) for the Revogeneﾮ SARS-CoV-2 assay was submitted to the FDA.